ABIOMED INC Action · US0036541003 · ABMD · 873886 (XNAS) USA · Healthcare — cotations et cours en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur ABIOMED INC

Résumé de la Note des Analystes

Conserver

Achat fort

Achat

Conserver

Vente

Vente forte

Pas de cours

Notation du Risque ESG

C+ Moyen

Flottant et Liquidité des Actions

Flottant Libre -

Actions en Flottant -

Actions en Circulation 45,09 M

Fonds investis

Les fonds suivants ont investi dans ABIOMED INC :

Fonds Direxion Fallen Knives ETF	Vol. en millions 396,05	Part (%) 3,39 %
Fonds ROBO Global Healthcare Technology and Innovation ETF	Vol. en millions 3.175,12	Part (%) 1,34 %
Fonds iShares US Medical Devices UCITS ETF USD (Acc)	Vol. en millions 517,73	Part (%) 0,93 %
Fonds Point Bridge GOP Stock Tracker ETF	Vol. en millions 96,36	Part (%) 0,76 %
Fonds Nationwide Maximum Diversification U.S. Core Equity ETF	Vol. en millions 824,89	Part (%) 0,69 %

Profil de l'entreprise pour ABIOMED INC Action

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.